SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
NCT04478019
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
245
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
SARS-CoV 2
Interventions
DRUG:
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Sponsor
University of Wisconsin, Madison